Sichuan Baili Pharmaceutical

Company snapshot

Sichuan Baili Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Cervical Cancer, Non-small Cell Lung Cancer, Breast Cancer, Non Small Cell Lung Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3), phase 1 (1).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sichuan Baili Pharmaceutical. Not investment advice.

• What is Sichuan Baili Pharmaceutical?

  Sichuan Baili Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Cervical Cancer, Non-small Cell Lung Cancer, Breast Cancer, Non Small Cell Lung Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent r

• Is Sichuan Baili Pharmaceutical publicly traded?

  Sichuan Baili Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sichuan Baili Pharmaceutical develop or market?

  No drug profiles are currently linked to Sichuan Baili Pharmaceutical. Pipeline programs may still list investigational assets.

• What are the latest developments for Sichuan Baili Pharmaceutical?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sichuan Baili Pharmaceutical focus on?

  Sichuan Baili Pharmaceutical focuses on Cervical Cancer, Non-small Cell Lung Cancer, Breast Cancer based on our analysis of their pipeline programs and drug development activities.